Ophthalmic pharma selling branded eye-care drugs (Vevye, Iheezo) and compounded medications through its ImprimisRx pharmacy.
Ophthalmic pharma selling branded eye-care drugs (Vevye, Iheezo) and compounded medications through its ImprimisRx pharmacy.
Started as a compounding pharmacy supplying eye doctors with custom-made formulations, which still brings steady sales, and is now building a branded-drug business through its own sales force, so approved products compete for the same prescribers. It also holds minority stakes in other eye-drug companies it helped create.
Moat: narrow (IP / patents, distribution). Combines branded FDA-approved drugs with a compounding pharmacy niche competitors don't easily replicate.
Headquarters: Nashville, Tennessee, US · Employees: 373
Size Harrow (HROW) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 2118th largest of 3,085 United States companies the cockpit tracks. Shares closed at $32.16 on 18 Nov 2026.
Performance Over six months the shares gained 4.2%, against -20.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 21.3% over the last twelve months (peer median +5.9%); the operating margin is 0.8% (peer median -18.6%).
Valuation It trades at 26.8× forward earnings against a peer median of 18.6× (3rd most expensive of 10).
Capital Return on invested capital runs 5.6 points below its cost of capital (6.4% WACC).
Credit Harrow has 1 bond outstanding ($300M), rated B3 by the agencies and trading like B- at a weighted spread of 483 bp.
Short interest Short interest is 18.9% of the free float (30 Oct 2026).
Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $303M | $272M | $200M | $130M | $88.6M |
| Revenue growth | — | +36% | +53% | +47% | — |
| Gross profit | $223M | $204M | $150M | $90.6M | $63.2M |
| EBITDA | $24.8M | $57.5M | $22.9M | $12.9M | $5.48M |
| Net income | -$28.5M | -$5.14M | -$17.5M | -$24.4M | -$14.1M |
| Free cash flow | -$20.4M | $43.0M | -$23.8M | $2.38M | -$892,000 |
| Capital expenditure | $19.5M | $1.10M | $38.7M | $153M | $7.77M |
| Total debt | $301M | $252M | $229M | $191M | $112M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Harrow HROW | $1.21B | +4% | +21% | 1% | 26.8× | n/a |
| Tarsus Pharmaceuticals TARS | $3.74B | +17% | +86% | -10% | n/a | 34.7% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HROW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.6% | -5.4% | 3rd highest of 21 |
| 6-month return | +4.2% | -20.6% | 3rd highest of 21 |
| Distance from 52-week high | -41.4% | -39.5% | 11th highest of 21 |
| Revenue growth (TTM) | +21.3% | +5.9% | 6th highest of 18 |
| Operating margin | 0.8% | -18.6% | 9th highest of 18 |
| Forward P/E | 26.8× | 18.6× | 3rd most expensive of 10 |
| ROIC minus cost of capital | -5.6 pp | -8.4 pp | 9th highest of 17 |
| EV / EBITDA | 57.8× | n/a | — |
| Net debt / EBITDA | 9.1× | n/a | — |
| Bond spread | 483 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
Harrow has 1 bond outstanding with $300M face value. The agencies rate it B3; its bonds trade like B-. Weighted yield 9.44%, a spread of 483 bp over government bonds.